[go: up one dir, main page]

WO2008030964A2 - Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits - Google Patents

Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits Download PDF

Info

Publication number
WO2008030964A2
WO2008030964A2 PCT/US2007/077763 US2007077763W WO2008030964A2 WO 2008030964 A2 WO2008030964 A2 WO 2008030964A2 US 2007077763 W US2007077763 W US 2007077763W WO 2008030964 A2 WO2008030964 A2 WO 2008030964A2
Authority
WO
WIPO (PCT)
Prior art keywords
blood
zeolite
calcium
noncalcium
zeolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/077763
Other languages
English (en)
Other versions
WO2008030964A3 (fr
Inventor
Robert L. Bedard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Honeywell UOP LLC
Honeywell International Inc
Original Assignee
Honeywell International Inc
UOP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honeywell International Inc, UOP LLC filed Critical Honeywell International Inc
Priority to CN200780033033A priority Critical patent/CN101677848A/zh
Priority to EP07841971A priority patent/EP2059187A2/fr
Publication of WO2008030964A2 publication Critical patent/WO2008030964A2/fr
Publication of WO2008030964A3 publication Critical patent/WO2008030964A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to blood clotting agents/medical devices and methods of controlling bleeding in animals and humans. More particularly, the present invention relates to the effectiveness of zeolites that have not been ion exchanged with calcium in promoting blood clotting provided that calcium ions are separately added along with the zeolites to the wound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des zéolites à échange de calcium qui sont efficaces dans une hémostase. La raison pour laquelle des zéolites à échange de Ca sont nécessaires n'a pas été expliquée dans la technique antérieure, excepté que la présence d'ions Ca2+ est importante dans le mécanisme de coagulation. On sait maintenant que l'ajout d'ions Ca2+ ralentit réellement la coagulation du sang. L'utilisation de zéolites de Ca apparaît comme étant efficace dans une hémostase simplement du fait qu'elles ne suppriment pas le Ca2+ critique du sang par un échange d'ions. Une zéolite de NaA pourvue d'une quantité efficace de sel de Ca2+ ajouté est presque aussi active dans une coagulation que la forme à échange de Ca de zéolite de CaA.
PCT/US2007/077763 2006-09-08 2007-09-06 Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits Ceased WO2008030964A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200780033033A CN101677848A (zh) 2006-09-08 2007-09-06 具有加入的钙盐的非钙沸石在止血装置和产品中的用途
EP07841971A EP2059187A2 (fr) 2006-09-08 2007-09-06 Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53036906A 2006-09-08 2006-09-08
US11/530,369 2006-09-08

Publications (2)

Publication Number Publication Date
WO2008030964A2 true WO2008030964A2 (fr) 2008-03-13
WO2008030964A3 WO2008030964A3 (fr) 2008-05-08

Family

ID=39158050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077763 Ceased WO2008030964A2 (fr) 2006-09-08 2007-09-06 Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits

Country Status (3)

Country Link
EP (1) EP2059187A2 (fr)
CN (1) CN101677848A (fr)
WO (1) WO2008030964A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2414225C1 (ru) * 2009-12-10 2011-03-20 Валерий Владимирович Бояринцев Местное гемостатическое средство

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
AU719490B2 (en) * 1996-04-25 2000-05-11 Unilever Plc Tea processing with zeolites
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US6100414A (en) * 1998-04-02 2000-08-08 Eastman Chemical Company Cyclopentadienyl transition metal compounds useful as polymerization catalysts
US6521265B1 (en) * 2000-02-09 2003-02-18 Biolife, L.L.C. Method for applying a blood clotting agent
WO2002030479A1 (fr) * 2000-10-13 2002-04-18 On Site Gas Systems, Inc. Bandage utilisant des tamis moleculaires
CA2456034A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US6989166B2 (en) * 2001-12-20 2006-01-24 N.V. Nutricia Soft drink replacer
EP1663090A4 (fr) * 2003-09-12 2010-07-21 Z Medica Corp Agent hemostatique de zeolite de calcium
US20060178609A1 (en) * 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2414225C1 (ru) * 2009-12-10 2011-03-20 Валерий Владимирович Бояринцев Местное гемостатическое средство

Also Published As

Publication number Publication date
EP2059187A2 (fr) 2009-05-20
CN101677848A (zh) 2010-03-24
WO2008030964A3 (fr) 2008-05-08

Similar Documents

Publication Publication Date Title
EP1667623B1 (fr) Agent hemostatique partiellement hydrate
Pourshahrestani et al. Well-ordered mesoporous silica and bioactive glasses: promise for improved hemostasis
KR101330011B1 (ko) 흡착제-함유 지혈기구
US8883194B2 (en) Adsorbent-containing hemostatic devices
US20080254147A1 (en) Method of providing hemostasis in anti-coagulated blood
US20090047366A1 (en) Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants
US20080145455A1 (en) Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents
US7595429B2 (en) Calcium zeolite hemostatic agent
EP1679087B1 (fr) Matériaux contenant du tamis moléculaire ayant un diamètre de particules agrandi pour la formation de caillots sanguins
WO2008128149A2 (fr) Procédé d'hémostase dans du sang anti-coagulé
WO2008030947A2 (fr) Utilisation de zéolithes échangeuses de calcium inactivées dans des dispositifs et produits hémostatiques
WO2008030964A2 (fr) Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits
EP2101794A2 (fr) Matières solides inorganiques qui accélèrent la coagulation du sang

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780033033.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07841971

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007841971

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2228/DELNP/2009

Country of ref document: IN